Sfunga Therapeutics Overview

  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $30M
Latest Deal Amount
  • Investors
  • 1

Sfunga Therapeutics General Information

Description

Provider of clinical research and development services intended to treat systemic and life-threatening fungal infections. The company's services focus on the improvement of Amphotericin B drug, enabling patients to receive a broad-spectrum of antifungal drug that is completely non-toxic in mammalian cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • Boston, MA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sfunga Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 22-Jan-2018 $30M 0000 0000 Completed Startup
To view Sfunga Therapeutics’s complete valuation and funding history, request access »

Sfunga Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 000
To view Sfunga Therapeutics’s complete cap table history, request access »

Sfunga Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Martin Burke Ph.D Founder
To view Sfunga Therapeutics’s complete executive team members history, request access »

Sfunga Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Illinois Ventures Venture Capital Minority 000 0000 000000 0
To view Sfunga Therapeutics’s complete investors history, request access »